Cardiovascular diseases (CVD) are the leading cause of death in the EU accounting for 1.9 million deaths each year (40% of all deaths in the EU) with an estimated associated cost of almost €196 billion per year. Despite these numbers, CVD can be successfully treated when detected early and managed according to best practices.
The objective of PHOCNOSIS is the development of a nanotechnology-based analysis device for the implementation of early CVD diagnosis programs, what is a key factor for reducing the mortality rates.

The Project

The PHOCNOSIS project aims at the development and the preclinical validation of a nanotechnology-based handheld point-of-care testing (POCT) analysis device for its application in the early diagnosis of cardiovascular diseases (CVD). The diagnosis will be carried out by means of the fast (<10 minutes), ultra-sensitive (<1 ng/L) and label-free detection of multiple cardiac biomarkers, using a small volume of whole blood (<100 μL). This POCT analysis device will significantly help in the implementation of mass screening programs, with the consequent impact on clinical management, reducing also costs of treatments, and increasing survival rates.

The PHOCNOSIS analysis device will be based on two state-of-the-art technological elements in order to obtain a compact and highly sensitive final device. First, an integrated micro-/nanofluidic system will be used for biomarkers separation, purification and concentration, targeting an effective concentration increase by a factor greater than 1000x for the targeted biomarkers. Then, the concentrated biomarkers will be detected using a novel nanophotonic-based sensing technique, envisaging a final combined detection limit below 1 ng/L. This novel sensing technique allows us to obtain systems which are low-cost, compact and with a lower complexity, thus making them suitable for the development of portable devices for POCT. The PHOCNOSIS project will target the deployment of disposable biochips with an envisaged cost below €3 to be used in a handheld analysis device with an envisaged cost below €3000.

Special attention will be paid within the PHOCNOSIS project to explore the potential deployment and commercialisation of the analysis device, by means of the involvement of relevant academic and industrial partners, as well as end users.

Funded by the Horizon 2020

This project is funded by the Horizon 2020 Framework Programme of the European Union

Title: Advanced nanophotonic point-of-care analysis device for fast and early diagnosis of cardiovascular diseases
Period: 01/09/2015 to 31/08/2018
Reference: H2020-PHC-634013

European Union logo



You can now download a presentation describing the approach and the main technologies involved in the development of the PHOCNOSIS analysis device.

Contact Us

Dr. Jaime García Rupérez
Universitat Politècnica de València
Nanophotonics Technology Center
Building 8F, 2nd floor
T. +34 96 387 70 00 (Ext. 88116)